Enovix Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Enovix Corporation trades at $4.9 (market cap $1.06B), while Inovio Pharmaceuticals Inc trades at $0.73 (market cap $78.55M). The key difference: Enovix Corporation is far larger — about 13.5× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| ENVX | INO | |
|---|---|---|
Market Cap | $1.06B | $78.55M |
Sector | Technology | Health |
52-Week High | $13.19 | $2.87 |
52-Week Low | $3.68 | $0.66 |
Enterprise Value | $1.07B | $49.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →